Holen Sie sich die Stockscreener-App
2.525
1.18%
-0.015
Schlusskurs vom Vortag:
$2.54
Offen:
$2.5
24-Stunden-Volumen:
16,581
Relative Volume:
0.07
Marktkapitalisierung:
$114.02M
Einnahmen:
$8,000
Nettoeinkommen (Verlust:
$-33.58M
KGV:
-2.9577
EPS:
-0.8537
Netto-Cashflow:
$-27.88M
1W Leistung:
-1.57%
1M Leistung:
-5.64%
6M Leistung:
-11.31%
1J Leistung:
-31.61%
1-Tages-Spanne:
$2.50
$2.54
1-Wochen-Bereich:
$2.39
$2.58
52-Wochen-Spanne:
$2.29
$8.535
Genelux Corp Stock (GNLX) Company Profile
Firmenname
Genelux Corp
Sektor
Branche
Telefon
805-267-9889
Adresse
2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE
Compare GNLX vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GNLX
Genelux Corp
|
2.52 | 114.92M | 8,000 | -33.58M | -27.88M | -0.8537 |
VRTX
Vertex Pharmaceuticals Inc
|
522.22 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
800.12 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
999.14 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
139.10 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.35 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Genelux Corp Stock (GNLX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-21 | Eingeleitet | Lake Street | Buy |
| 2024-10-29 | Eingeleitet | Guggenheim | Buy |
| 2024-08-28 | Eingeleitet | ROTH MKM | Buy |
| 2023-11-27 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-09-12 | Eingeleitet | Maxim Group | Buy |
| 2023-02-15 | Eingeleitet | The Benchmark Company | Speculative Buy |
Alle ansehen
Genelux Corp Aktie (GNLX) Neueste Nachrichten
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Genelux chief scientific officer Yu Yong sells $26,658 of stock By Investing.com - Investing.com South Africa
Genelux CEO Zindrick sells $91,899 in common stock - Investing.com India
Genelux CTO Joseph Cappello sells $28,112 in company stock - Investing.com
Genelux CTO Joseph Cappello sells $28,112 in company stock By Investing.com - Investing.com Canada
Benchmark reiterates Genelux stock rating on cancer therapy progress - Investing.com
Equities Analysts Offer Predictions for Genelux Q3 Earnings - MarketBeat
Analysts Are Bullish on Top Healthcare Stocks: Auxly Cannabis Group (CBWTD), Genelux Corp. (GNLX) - The Globe and Mail
Genelux Corp (GNLX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Genelux: Undervalued Oncolytic Virus Leader as Olvi-Vec Nears Key Phase 3 Ovarian Cancer Catalyst - TipRanks
Genelux (NASDAQ:GNLX) Downgraded to "Strong Sell" Rating by Wall Street Zen - MarketBeat
Genelux Reports Second Quarter 2026 Results and Advances Olvi-Vec Clinical Programs in Ovarian and Lung Cancer - Quiver Quantitative
Genelux Corporation Reports Second Quarter Financial Results and Provides Business Updates - Yahoo Finance
Genelux (NASDAQ:GNLX) Issues Earnings Results - MarketBeat
Genelux (GNLX) deepens losses while funding Phase 3 cancer trial and warning on cash runway - Stock Titan
GENELUX Corp 6M 2026: Revenue $0 Net loss $(18.4M), EPS $(0.41) — 10-Q Summary - TradingView
Genelux Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Genelux Corp (GNLX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Genelux Corporation (GNLX) Slips 1.11% as Shares Test Support Near $2.54High Low Breadth - dars.gov.et
Insiders Sold Genelux At US$3.34, Meanwhile Stock Sits Near US$2.51 - Sahm
Genelux Corp expected to post a loss of 20 cents a shareEarnings Preview - TradingView
Genelux (GNLX) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Genelux Corp (GNLX) Balance Sheet - tradingkey.com
Genelux Corp (GNLX) Cash Flow - TradingKey
Genelux Corp (GNLX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Genelux Corp (GNLX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Genelux Corp (GNLX) Income Statement - TradingKey
GNLX|Genelux Corp|Price:2.890|Chg%:-0.070 - TradingKey
Genelux Corp (GNLX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Genelux (NASDAQ:GNLX) Shares Down 2.4%Should You Sell? - marketbeat.com
Insider Shake-Up at Genelux Corp Sparks Investor Attention - TipRanks
GENELUX (NASDAQ: GNLX) director sells 12,000 shares to cover RSU tax bill - Stock Titan
[144] GENELUX Corp SEC Filing - Stock Titan
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Genelux Announces Publication of Translational Analysis Supporting Immune Activation and Chemotherapy Sensitization with Olvi‑Vec in Ovarian Cancer - The Manila Times
Genelux says Olvi-Vec may reawaken platinum response in ovarian cancer - Stock Titan
Genelux Corp. Actuals & Estimates (NASDAQ:GNLX) - TradingView
Genelux Corp (GNLX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Genelux Corporation 8-K Filing: Company Details, Nasdaq Listing, and Emerging Growth Status (June 2026) - Minichart
Genelux elects director and ratifies auditor at annual shareholder meeting - Investing.com
Genelux elects director and ratifies auditor at annual shareholder meeting By Investing.com - Investing.com Nigeria
Form 8K Genelux Corp For: 22 June By Investing.com - Investing.com South Africa
Genelux (GNLX) 2026 meeting backs director John Smither and auditor - Stock Titan
Genelux (GNLX) director receives RSU and stock option grants - Stock Titan
Genelux (GNLX) director receives RSUs and stock options in new grant - Stock Titan
GENELUX (GNLX) CFO receives 278,906 restricted stock units as equity grant - Stock Titan
Genelux (NASDAQ: GNLX) grants 233,957 RSUs to General Counsel Eric Groen - Stock Titan
GENELUX (GNLX) CTO granted 174,841 RSUs under 2022 equity plan - Stock Titan
GENELUX (NASDAQ: GNLX) director James L. Tyree receives RSU and option grants - Stock Titan
Genelux (NASDAQ: GNLX) grants CEO 730,601 RSUs under 2022 plan - Stock Titan
GENELUX (GNLX) Chief Scientific Officer awarded 119,318 RSUs in equity grant - Stock Titan
Finanzdaten der Genelux Corp-Aktie (GNLX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.72%
1.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):